Metastasis in breast cancer carries a disproportionately worse prognosis than localized primary disease. To identify microRNAs (miRNA) involved in metastasis, the expression of 254 miRNAs was measured across the following cell lines using microarray analysis: MDA-MB-231 breast cancer cells, cells that grew as a tumor in the mammary fat pad of nude mice (TMD-231), metastatic disease to the lungs (LMD-231), bone (BMD-231) and adrenal gland (ADMD-231). A brain-seeking variant of this cell line (231-BR) was used additionally in validation studies. Twenty miRNAs were upregulated and seven were downregulated in metastatic cancer cells compared with TMD-231 cells. The expression of the tumor suppressor miRNAs let-7 and miR-22 was consistently downregulated in metastatic cancer cells. These metastatic cells expressed higher levels of putative/proven miR-22 target oncogenes ERBB3, CDC25C and EVI-1. Introduction of miR-22 into cancer cells reduced the levels of ERBB3 and EVI-1 as well as phospho-AKT, an EVI-1 downstream target. The miR-22 primary transcript is located in the 5 0 -untranslated region of an open reading frame C17orf91, and the promoter/enhancer of C17orf91 drives miR-22 expression. We observed elevated C17orf91 expression in non-basal subtype compared with basal subtype breast cancers. In contrast, elevated expression of EVI-1 was observed in basal subtype and was associated with poor outcome in estrogen receptor-negative breast cancer patients. These results suggest that metastatic cancer cells increase specific oncogenic signaling proteins through downregulation of miRNAs. Identifying such metastasisspecific oncogenic pathways may help to manipulate tumor behavior and aid in the design of more effective targeted therapies.
Introduction
Breast cancer metastasis is the dominant mechanism underlying treatment failure and mortality (Steeg, 2006) . Metastatic cancer cells have been shown to carry a distinct biological profile from that of primary tumor cells by displaying characteristics such as enhanced survival, motility, invasiveness and resistance to chemotherapy (Kang et al., 2003; Gupta et al., 2005) . Investigating the extent to which metastatic cancer cells differ from primary tumor cells with respect to gene expression is a newly developing field. At the center of these investigations are microRNAs (miRNAs). These small non-coding RNAs are now thought to be one of the major regulators of gene expression (Nicoloso et al., 2009) .
The role of miRNAs in cancer pathogenesis is tumor subtype specific. Recent reports describe miRNA expression patterns in breast cancer in relation to hormone receptor status (Mattie et al., 2006; Blenkiron et al., 2007) . For example, the expression of let-7 family members is lower in HER-2(ERBB2)-positive breast cancers compared with other cancer types. In total, 43 miRNAs are expressed at a higher level in HER-2-positve breast cancers compared with HER-2-negative breast cancers. Similarly, 43 miRNAs are expressed at higher levels in estrogen receptor a (ERa)-positive breast cancers compared with ERa-negative breast cancers. Luminal type A breast cancers, which express ERa and correspond to a good prognostic subgroup, show elevated expression of miR-10a, miR-10b, miR-21, miR-126*, miR-130a, miR-31, miR-382, miR-152, miR-100, miR-99a, miR-30-a-3p, miR-30a-5p, miR-224, miR-214, let-7a, let-7b, let-7c, let-7f and miR-342. Estrogen regulates the expression of several of these miRNAs (Bhat-Nakshatri et al., 2009; Castellano et al., 2009; Maillot et al., 2009) . Basal type of breast cancers, which are hormone receptor negative and correspond to a significantly worse prognostic subgroup, express higher levels of miR-150, miR-142-3p, miR-142-5p, miR-148a, miR-106a, miR-106b, miR-18a, miR-93, miR-155, miR-25, miR-187 and miR-135b . Interestingly, HER-2-positive tumors show a similar miRNA expression profile to basal type tumors with the exceptions of miR-106a, miR-18a, miR-93, miR-155 and miR-135b. However, none of these studies compared the miRNA expression pattern between primary and metastatic tumors. Utilizing the highly aggressive and basal type MDA-MB-231 (called MD-231 hereafter) breast cancer cell line as a metastasis model, we compared the miRNA expression profiles of parental MD-231 cells, primary tumor cells (TMD-231) as well as metastatic disease from the brain (231-BR), lung (LMD-231), adrenal (ADMD-231) and bone . Using microarray analysis, we found differential expression of miRNAs between metastatic cell lines compared with the primary tumor. Most notable among miRNAs that showed altered expression was miR-22, which was downregulated in the metastatic clones. We describe a pattern of metastatic site-specific differential protein expression of predicted/proven targets of miR-22 and describe how reduced levels of miR-22 in metastatic cells contribute to activation of oncogenic pathways. clones displayed elevated levels of 20 miRNAs and reduced levels of 7 miRNAs compared with MD-231 or TMD-231 cells (Table 1) . Selection of cells through mammary fat pad injection alone appears to change the miRNAs expression pattern as 22 miRNAs were elevated and 8 miRNAs were downregulated in TMD-231 cells and its metastatic variants compared with parental MD-231 cells (Table 2) . Of these, miR-22 showed the most significant repression of B50% in metastatic clones compared with parental MD-231 cells. LMD-231 clones displayed a unique expression pattern in which four let-7 family members were downregulated compared with the other clones (Table 3 ). Very few changes specific to BMD-231 and ADMD-231 were observed.
Results

MiRNA expression
Differential expression of let-7f and miR-22 in primary and metastatic cells It was recognized recently that the measurement of miRNA expression results obtained using various methods including miRNA profiling and quantitative reverse transcription-PCR (qRT-PCR) were not always compatible (Koshiol et al., 2010) . Taking these observations into consideration, we performed qRT-PCR using primers specific to mature let-7f and miR-22 across our cell lines to further establish their differential expression in various cell lines (Figure 2 ). This analysis also included the brain metastatic variant 231-BR cells (Gril et al., 2008) . As 231-BR cells originated from a different laboratory, parental cells used to generate these cells from that same laboratory (MD-231P) were used for side-by-side comparison. Let-7f expression was similarly low in metastatic clones compared with MD-231 and TMD-231 ( Figure 2a ). We are not sure why the level of this miRNA was elevated in TMD-231 compared with the parental cell line. Differences between the variants of a particular metastatic clone were not statistically significant, which was discordant with the microarray results (Table 3) . Nonetheless, the results clearly showed reduced expression of let-7f in metastatic clones compared with parental and/or primary tumor-derived clones with minimal difference among metastatic clones. MD-231 and TMD-231 showed a modest difference in the expression of miR-22 with metastatic clones showing even further reduction in expression of this miRNA (Pp0.0005). Expression was least in 231-BR followed by BMD-231 ( Figure 2b ). The expression of miR-22 was lower in LMD-231 and BMD-231 cells compared with MD-231 cells with U6 or 5S as normalization controls (data not shown).
MiR-424 displayed 4.3-fold elevated expression in TMD-231 and metastatic clones compared with MD-231 cells (Table 2) . MiR-424 is located on the Xchromosome and the corresponding region is activated in sporadic basal breast cancers as well as in BRCA1 mutant cancers suggesting its relevance to these aggressive types of cancer (Richardson et al., 2006) . As per miRgen, PCDHA13 (procadherin 13), PTCH1 (patched 1, a tumor suppressor in hedgehog pathway) and RARb (retinoic acid receptor b, a tumor suppressor) are its predicted targets. In qRT-PCR validation assays, although there was considerable experimental variation in expression in metastatic cell lines, a statistically significant increase was observed only in TMD-231 cells compared with MD-231 cells with RNU66 as a normalization control ( Figure 2c and data not shown). With 5S RNA as a normalization control, a 3.3-fold increase in expression (P ¼ 0.01) was observed in ADMD-231 cells compared with MD-231 cells (data not shown).
Expression levels of predicted miR-22 targets in primary tumor and metastatic cells Based on targetscan and miRGen predictions, more than 200 genes are putative targets of miR-22. Genes relevant to breast cancer include AKT3, ERBB3, SATB2, HDAC4, CDC25C and SIRT1. Additionally, miR-22 has been shown to target the transcription factors SP-1, EVI-1 oncogene, ERBB3 and ERa ( Sun et al., 2008; Pandey and Picard, 2009; Nagaraja et al., 2010) . miR-22-mediated regulation of ERa is not relevant to this study as cells used in this study are ERanegative. First, we determined whether miR-22 expression levels showed any correlation with the levels of its putative/proven target genes. ERBB3 protein, but not AKT3 and CBL proteins, was elevated in metastatic clones, particularly in LMD-231 and ADMD-231 cells, compared with MD-231 cells (Figure 3a) . Similarly, EVI-1 expression showed negative correlation with miR-22. In particular, 231-BR cells showed remarkably higher levels of EVI-1 compared with MD-231P cells. EGFR, although not a direct target of miR-22, but is functionally linked to ERBB3, is differentially expressed; both protein and transcript levels were elevated in TMD-231 and all metastatic clones compared with parental MD-231 cells (Figures 3a and b) . Both SP-1 and CDC25C showed variable expression among different cell lines; however, their expression did not negatively correlate with miR-22 expression in all cell types. Between MD-231p and 231-BR cells, CDC25C expression was higher in 231-BR cells (Figure 3a) .
The degree of miRNA-mediated target downregulation often tends to be quantitatively modest and is evident mostly upon overexpression (Inui et al., 2010) . To investigate whether miR-22 directly regulates the expression of above genes, we generated MD-231P cells overexpressing miR-22 (MD-231-miR-22) (Figure 3c ). The expression levels of EVI-1 and ERBB3, but not AKT3, SP-1 and SP-3, were substantially lower in MD-231-miR-22 cells compared with MD-231P cells with vector alone (MD-231P-pQXIN) (Figure 3d and data not shown).
EVI-1 expression is linked to PI3Kinase-dependent activation of AKT and miR-22 overexpression is expected to reduce AKT activation (Liu et al., 2006; Nagaraja et al., 2010) . We examined this possibility by measuring phospho-AKT levels in MD-231P-pQXIN and MD-231P-miR-22 cells. Basal phospho-AKT levels were substantially lower in MD-231P-miR-22 cells compared with MD-231P-pQXIN cells (Figure 3e ). We also note that 231-BR cells, which express lower levels of miR-22, but higher levels of EVI-1 compared with MD-231P cells, contain higher levels of pAKT (Figure 3e ). MD-231P-pQXIN cells were more migratory compared with MD-231P-miR-22 cells in scratch wound assay, which may be linked to differential levels of pAKT in these cells (Figure 3f) . Additionally, a quantitative migration assay revealed B25% lower migration of MD-231P-miR-22 cells compared with MD-231P-pQXIN cells over a 24-h period (Figure 3f ). Taken together, these results reveal specific changes in the expression levels of oncogenic proteins in metastatic variants compared with primary tumor cells in our model system. Some of these changes may be linked to differential miRNA expression.
Elevated expression levels of C17orf91, which harbor miR-22, correlate with better outcome, luminal phenotype and lower ERBB3 and EVI-1 levels in primary tumors Previous studies with limited breast cancer samples have shown lower miR-22 expression in ERBB2-positive breast cancers compared with ERBB2-negative tumors and higher expression in ER þ and PR þ tumors compared with ERÀ and PRÀ tumors, respectively; however, its expression status in basal or triple negative breast cancer is unknown (Mattie et al., 2006) . We took advantage of the fact that miR-22 is located in the 5 0 -untranslated region of a transcript called C17orf91 on chromosome 17 and utilizes the enhancer/promoter region of this gene for transcription to indirectly determine the expression levels of miR-22 in published gene expression databases (Chang et al., 2008) . We used the recently reported online tool to correlate C17orf91 expression with outcome in breast cancer patients (Gyorffy et al., 2010) . Elevated C17orf91 expression correlated with significantly higher relapse-free survival (Figure 4a ). Metastasis-free survival also showed a similar trend, but did not reach statistical significance. When truly prognostic data sets (no systemic therapy) were used in the analysis, elevated C17orf91 expression correlated with poor relapse-free survival (data not shown). Whether these contrasting observations are linked to the therapeutic response is unknown. We used additional microarray data sets in Gene Expression Omnibus to determine correlation between C17orf91 and EVI-1 expression. C17orf91 expression was lowest in basal breast cancers compared with nonbasal cancers or normal breast cells (Figure 4b ). In contrast, EVI-1 expression was elevated in basal breast cancers compared with non-basal cancers or normal breast. C17orf91 (miR-22) expression appeared to be negatively regulated by hypoxia-inducible transcription factors as MCF-7 cells exposed to hypoxia expressed lower levels of C17orf91 compared with the same cells exposed to hypoxia under HIF1a, HIF2a or both depleted conditions (Figure 4c ). In the same set of experiments, EVI-1 expression under hypoxic conditions was lower in cells depleted of HIF2a and both HIF1a and HIF2a compared with cells depleted of HIF1a or treated with control siRNA (Figure 4c ).
EVI-1 expression in ERa-negative breast cancers is associated with poor outcome
The results of our in vitro studies showing clear negative correlation between miR-22 and EVI-1 expression in metastatic breast cancer cells prompted additional evaluation of EVI-1 for its relevance in breast cancer prognosis. In ERa-negative subgroup of patients, who often develop metastatic disease, higher expression of EVI-1 in tumors was associated with reduced relapsefree, metastasis-free and overall survival (Figure 5a ). In ERa-positive subgroup, EVI-1 expression did not show any correlation with patient outcome (Figure 5b ). When all patients were considered, elevated EVI-1 expression was associated with reduced metastasis-free but not overall survival. For unknown reason, higher EVI-1 expression appeared to correlate with improved relapsefree survival (Figure 5c ). When the analysis was restricted to truly prognostic data sets, elevated EVI-1 expression was associated with poor distant metastasisfree (P ¼ 0.031) but not recurrence-free or overall survival. Overall, our results showed an association between reduced miR-22/C17orf91 levels, elevated EVI-1 and poor patient outcome.
Discussion
There is an explosion of data emerging from laboratories worldwide describing the pivotal role of miRNAs in tumorigenesis. From their discovery in 1997 to the present, over 700 such molecules have been identified (O'Day and Lal, 2010). These non-coding RNAs have been linked to all aspects of cancer from initiation, proliferation, motility and invasion to metastasis (Hurst et al., 2009; Inui et al., 2010) . They are thought to function much like proto-oncogenes and tumor suppressor genes, whereby alterations in their expression lead to aberrant cellular behavior. Examples of tumor suppressor miRNAs include let-7, miR-335, miR-126 and miR-206 (Tavazoie et al., 2008) . The downregulation of these miRNAs had many effects, but the most predominant function is increasing the metastatic potential via upregulation of genes involved in motility and proliferation. Specifically, miR-335 loss leads to altered expression of genes such as SOX4, neuropilin 1 and semaphoring 3C, which control progenitor cell development and migration (Hoser et al., 2007) . Studies on miR-126 show the context-specific actions in tumorigenesis. In breast cancer, loss of miR-126 leads to increased cell proliferation without effects on motility, whereas in non-small cell lung cancers, loss of miR-126 leads to increased motility without effects on proliferation (Nicoloso et al., 2009 ). Other such miRNAs include miR-29c involvement in modulating the tumor microenvironment and miR-146 modulation of amoeboid motility (Friedl and Wolf, 2003 ; Ramaswamy et al., 2003) . Several other miRNAs have been described to have a function in metastasis, but not primary tumor growth (Hurst et al., 2009) . miR-31 is one among them, which is downregulated in metastatic lesions compared with primary tumors; however, we did not observe a change in miR-31 expression between primary tumors and metastatic cells because the cell lines used in our study did not express this miRNA (Valastyan et al., 2009) . From our studies, we found a strong correlation between decreased expression of let-7f and miR-22 and breast cancer metastasis. From their downregulation, we can infer that these miRNAs have a metastasis suppressor function; loss of their expression leads to increased expression of their downstream oncogenic products. The role of let-7f in tumorigenesis and metastasis is well known (O'Day and Lal, 2010) ; therefore, we did not place much emphasis on this miRNA. However, miR-22 is a relatively new player and has been linked to cellular metabolism and chronic inflammatory diseases such as osteoarthritis (Iliopoulos et al., 2008) . Normal mammary stem cells express high levels of miR-22 and little-to-no let-7; however, during progressive differentiation, the expression of miR-22 decreases and expression of let-7 family members is induced (Ibarra et al., 2007) . These results suggest a role for miR-22 in maintaining a stem cell phenotype in the normal mammary gland (Ibarra et al., 2007) . However, it appears that the role of miR-22 is different in a metastasis setting. miR-22 targets the extracellular environment via matrix metalloproteinases and interleukins and thus has a function in inflammatory conditions (Iliopoulos et al., 2008) . Putative downstream targets of miR-22 include ERBB3, CDC25C, EVI-1, SIRT1, AKT3, SATB2, HDAC4, CBL, peroxisome proliferator activated receptor a and BMP7. Peroxisome proliferator activated receptor a and BMP7 have been validated in other studies as targets of miR-22 (Iliopoulos et al., 2008) ; however, we did not find them to be targets of miR-22 in breast cancer cells (data not shown). ERBB3 and EVI-1 have recently been shown to be targets of miR-22 in clear cell ovarian cancer (Nagaraja et al., 2010) . Overexpression of miR-22 reduced the levels of ERBB3 and EVI-1 in breast cancer cells confirming that they both were targets of miR-22. Collectively, it appears that potent oncogenes linked to breast cancer progression are the targets of miR-22. Although it is extremely unlikely that only miR-22 regulates the levels of these proteins in metastatic cancer cells compared with parental tumor cells, several organ-specific variants expressed higher levels of miR-22 targets compared with primary tumor cells. For example, ERBB3 levels were higher in the lung and adrenal metastatic clones compared with MD-231 cells. ERBB3, EVI-1 and CDC25C levels were higher in 231-BR cells compared with MD-231P cells. All metastatic cancer cells expressed higher levels of EGFR both at the transcript and protein levels; therefore, EGFR:ERBB3 heterodimers may be predominant in metastatic cancer cells compared with tumors cells.
ERBB3 lacks kinase activity and, therefore, it received little attention until recently. It is now believed to have a significant function in conferring resistance to growth factor receptor tyrosine kinase inhibitors (Sergina et al., 2007) . Whether metastatic cancer cells are more resistant to these inhibitors compared with primary tumors cells remains to be determined. PI3Kinase/AKT is one of the major downstream targets of ERBB3 (Campbell et al., 2010) . Interestingly, EVI-1 also activates this pathway; activation of PI3 kinase/AKT is linked to drug resistance (Liu et al., 2006) . It is likely that two redundant pathways of PI3Kinase/AKT activation in metastatic cancer cells make these cells highly resistant to chemotherapeutic drugs. Indeed, in our in vitro studies, the metastatic variants were resistant to doxorubicin compared with parental cells (data not shown). However, miR-22 overexpression alone did not change sensitivity of MD-231P cells to doxorubicin or docetaxel, suggesting the involvement of additional signaling networks in resistance to chemotherapy (data not shown).
In addition to its role in PI3Kinase/AKT activation, EVI-1 is a major epigenetic regulator of gene expression and mainly targets genes associated with stemness phenotype (Kumano and Kurokawa, 2010) . EVI-1 induces PBX1, one of the major stemness-associated gene (Shimabe et al., 2009) . Therefore, reduced miR-22 expression in metastatic cells may lead to elevated expression of stemness-associated genes. EVI-1 has previously been linked to myeloid leukemia and myelodysplastic syndrome (Wieser, 2007) . Our studies in breast cancer cell lines, as well as the analysis of gene expression arrays from primary breast tumor samples suggest a role for this protein in breast cancer metastasis. As EVI-1 is a transcription factor capable of causing epigenetic changes through recruitment of histone methyltransferases (Goyama et al., 2010) , a modest alteration in its expression levels may be sufficient to cause a major shift in gene expression programs, helping cancer cells to adapt to sites of metastasis.
While most of our studies were confined to miR-22, we also observed several other miRNAs, whose altered expression may potentially contribute to metastasis. One example is miR-200a. Reduced expression of miR-200a in primary tumors is essential for cancer cells to acquire invasive phenotype through epithelial-to-mesenchymal transition (Gibbons et al., 2009) , whereas its overexpression in mammary tumor cell lines enhances mesenchymal-to-epithelial transition and increases macrometastasis (Dykxhoorn et al., 2009) . Consistent with this possibility, we observed elevated miR-200a in metastatic cancer cells compared with parental cells or TMD-231 cells. miR-17-5P has been suggested as a tumor suppressor in breast cancer; its expression was lower in lung metastatic cancer cells compared with other cell types (O'Day and Lal, 2010) . The protumorigenic and prometastatic miRNA miR-19b was upregulated in metastatic cells (Table 2) , whereas the antimetastatic miR-16 was downregulated in lung metastatic cells (Table 3) (Hurst et al., 2009) . However, there were few exceptions: metastatic cells expressed elevated levels of miR-101, which has been described as tumor suppressor in other cancer types (Varambally et al., 2008) . In summary, we have described results that suggest a role for miRNAs in changing the protein expression pattern in cancer cells depending on the site of metastasis. Further studies are required to investigate the impact of manipulating individual miRNAs on organ-specific metastasis and sensitivity to specific therapies.
Materials and methods
Cell lines
MDA-MB-231, TMD-231, BMD-231, LMD-231, ADMD-231 and 231-BR cells were maintained in MEM media supplemented with 10% fetal bovine serum, 10 nM insulin and penicillin/streptomycin. Our metastasis model involved injection of parental MDA-MB-231 into the mammary fat pad of nude mice. After B8 weeks time, the mice were killed, the primary tumors were harvested and select distant sites including bone, lung, adrenal and brain were examined for evidence of metastatic disease. Using this model system, only lung metastatic (LMD-231) cells could be obtained (Helbig et al., 2003) . Therefore, a slight variation on the previous model system was implemented. TMD-231 cells were injected via intracardiac route and after 8 weeks, the mice were killed, and BMD-231, ADMD-231 and 231-BR metastatic cell lines were successfully generated. Two variants of LMD-231 were used for microarray analysis, one that had metastasized from the mammary fat pad to the lungs and the other via intracardiac injection. Similarly, three clones of BMD-231 were used for microarray analysis-one isolated from the mandible, one from the vertebral column and the other from the tibia; all generated via intracardiac injection. Typically, metastatic lesions or whole organs were minced and incubated in 50 ml media containing collagenase IV (0.72 mg/ml) and hyaluronidase (0.2 mg/ml) for 3 h. Cells were washed in PBS and plated in regular media. After 2-3 days, cells were incubated in serum-free media for 2 days to reduce the number of fibroblasts. Additionally, flow cytometry with EpCAM confirmed that 495% of cells are cancer cells (data not shown). As 231-BR cells were developed in a different laboratory, the expression pattern of miRNAs and their targets in 231-BR was compared with parental cells maintained in that laboratory (MD-231P) (Gril et al., 2008) .
miRNA expression analysis
The small RNA fraction from all cell lines was prepared using the mirVana miRNA isolation kit (Ambion Inc., Austin, TX, USA). Hybridization to miRNA arrays has been described previously (Yu et al., 2007) . Assays were carried out in duplicate with RNA from MD-231, TMD-231, ADMD-231, two independent clones of LMD-231 and three independent clones of BMD-231. As all of the probes were printed twice on the microarray in two independent blocks, four measurements were available for every miRNA in each experimental condition. Signal intensity of tRNA-Thr was used for normalization between samples. Differentially expressed miRNAs were identified using a linear model that describes the relationship between cell type and probe blocks. Changes in let-7f and miR-22 expression were verified in three independent RNA preparations by qRT-PCR using TaqMan miRNA assays designed to detect and accurately quantify mature miRNAs (Applied Biosystems, Foster City, CA, USA). Primers specific to miR-22 (catalog #000398), miR-424 (catalog #000604), let-7f (catalog #000382) and RNU66 (catalog number 001002) were purchased from Applied Biosystems. Primers specific for 5S (catalog #201509) were purchased from Exiqon (Vedbaek, Denmark). Target genes of differentially expressed miRNAs were predicted using TargetScan and miRgen programs (Lewis et al., 2005) .
RT-PCR and quantitative real-time RT-PCR Independent samples of total RNA were prepared using the RNAeasy kit (Qiagen, Valencia, CA, USA). First strand cDNA was synthesized using random hexamers and superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). To quantify the level of EGFR mRNA, qRT-PCR was performed using the SyBr green mix according to the manufacturer's protocol (Applied Biosystems). Expression of b-actin was used as an internal control. Sequences of primers used will be provided upon request.
Generation of miR-22 overexpressing cell line and migration assay Genomic DNA harboring mature miR-22 sequences were amplified by PCR using the primers 5 0 -GGGGGATCCCT GGGGCAGGACCCT-3 0 and GGGGAATTCAACGTATC ATCCACCC-3 0 (chromosome 17:1563850-1564149, underlined sequences are cloning restriction enzyme sites) and cloned into BamH1-EcoR1 sites of the bicistronic retrovirus vector pcQXIN. Retrovirus packaging, transduction and selection of cells overexpressing miR-22 have been described previously (Chua et al., 2007) . Cell migration assay was performed using CytoSelect 24-well Cell Migration assay kit as per instruction from manufacturers (Cell Biolabs, Inc., San Diego, CA, USA).
Western blot analysis
Whole cell lysates were prepared in RIPA buffer and western blotting was performed as previously described (Bhat-Nakshatri et al., 2004) . The primary antibodies used were c-Myc, EGFR, TLR4, ERBB2, ERBB3 (Santa Cruz Biotechnology, Santa Cruz, CA), AKT3, EVI-1 (Cell Signaling, Danvers, MA, USA) and b-actin (Sigma Chemical Co., St Louis, MO, USA).
Statistical analysis
All experiments were performed at least in duplicate. The results of qRT-PCR were analyzed using GraphPad software (Graphpad.com). Analysis of variance was used to determine the P-values between mean measurements. A P-value of o0.05 was deemed statistically significant. Error bars on all histograms represent the standard error of the mean.
Expression analysis of primary tumors
Relationship between the expression levels of C17orf91, ERBB3 and EVI-1 in different breast cancer subtypes as well as in MCF-7 cells depleted of hypoxia-inducible factors was determined using the expression array data sets in Gene Expression Omnibus (Elvidge et al., 2006) . Relationship between EVI-1 expression and breast cancer outcome was determined using the gene expression data of 22 277 genes in 1809 breast cancer patients (Gyorffy et al., 2010) . All or only true prognostic data sets (no systemic therapy) were included in the analysis. These data sets are described in Gene Expression Omnibus accession numbers GSE11121 (Schmidt et al., 2008) , GSE7390 (Desmedt et al., 2007) and select data from GSE3494, GSE2990 and GSE2034 (Miller et al., 2005; Wang et al., 2005; Sotiriou et al., 2006) . C17orf91 expression was analyzed using the affymetrix probe set 214696_at (excellent probe set), whereas EVI-1 (MECOM) was measured using the probe set 221884_at (intermediate probe set).
